Hepatotoxicity

As the central organ for drug metabolism and detoxification, the liver is highly susceptible to toxicity. Early identification of hepatotoxicity risk in drug discovery and development helps reduce costly late-stage failures and supports informed decision-making in your pipeline.

Our in vitro toxicology services are designed to support early-stage drug discovery by providing predictive and actionable insights into hepatotoxicity and drug induced liver injury (DILI) risk. With a comprehensive portfolio of assays and cutting-edge technologies, we help you de-risk your IND candidates with confidence.

We offer hepatotoxicity assays using primary hepatocytes from multiple species (rodents, dog, human) to provide species-specific insights and enhance translational relevance. Our endpoints include biochemical assays, histopathology, and high-content imaging, delivering a comprehensive view of hepatotoxicity mechanisms.  

• Cytotoxicity/cell viability: LDH release or ATP content
• ‍Mitochondrial toxicity: Mitochondrial resazurin metabolism
• ‍Oxidative Stress: ROS (Reactive oxygen species) formation and Glutathione (GSH/GSSG) Assays ‍
• Steatosis: Detection of lipid accumulation in hepatocytes ‍
• Apoptosis: Apoptotic pathway analysis for mechanistic insights.

We offer a comprehensive range of instrumentation and cellular systems to help design the most appropriate assay, ensuring alignment with experimental goals and the generation of meaningful data.  We actively develop new methods, according to test guidelines or bespoke.